Craft
  • Home
  •  / BGI Genomics
BGI Genomics

BGI Genomics

Countries

100

H1, 2022

Revenue

¥6.7 B

FY, 2021

Market Capitalization

¥24.4 B

2022-11-03

BGI Genomics Summary

Company summary

Overview
BGI Genomics (华大基因, 深圳华大基因股份有限公司) is a company offering genomic sequencing and proteomic services. It engages in DNA and RNA sequencing, hereditary cancer screening, non-invasive prenatal screening, etc. The company also provides mass spectrometry, pharma, and COVID-19 solutions. BGI Genomics caters to academic institutions, pharmaceutical companies, health care providers, and other organizations.
Type
Public
Status
Active
Founded
1999
HQ
Shenzhen, CN | view all locations
Website
https://www.bgi.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key people

  • Wang Jian

    Wang Jian, Co-Founder and Chairman

    • Wang Shi

      Wang Shi, Co-Chairman

      • Yang Huanming

        Yang Huanming, Co-Founder, Director and Chairman

        • Liu Siqi

          Liu Siqi, Co-Founder and Supervisor

          Operating MetricsView all

          Trademarks

          809
          49.8%

          H1, 2022

          Patents Issued

          566
          37.7%

          H1, 2022

          Customers (Hospitals, China)

          231
          15.5%

          FY, 2019

          LocationsView all

          12 locations detected

          • Shenzhen, Guang Dong Sheng HQ

            China

            Building NO.7, BGI Park, No.21 Hongan 3rd Street

          • Cambridge, MA

            United States

            One Broadway, 14th Floor

          • Brisbane, QLD

            Australia

            L6, CBCRC Building, QIMR, 300 Herston Rd

          • Shenzhen, Guang Dong Sheng

            China

            Building 11, Beishan Industrial Zone

          • Copenhagen

            Denmark

            Ole Maaløes Vej 3

          • Addis Ababa, Addis Ababa

            Ethiopia

            Bole Lemi Industry Park Phase II

          and 6 others

          BGI Genomics Financials

          Summary financials

          Revenue (Q3, 2022)
          ¥1.4B
          Gross profit (Q3, 2022)
          ¥764.9M
          Net income (Q3, 2022)
          ¥141.2M
          Cash (Q3, 2022)
          ¥6.0B
          EBIT (Q3, 2022)
          ¥131.1M
          Enterprise value
          $19.6B

          Footer menu